Safety and efficacy for day 1 administration of gemcitabine and cisplatin

Safety and efficacy for day 1 administration of gemcitabine and cisplatin - Safety and efficacy for day 1 administration of gemcitabine and cisplatin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031015

Enrollment

Registered

2018-01-27

Start date

2018-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma

Interventions

gemcitabine and cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: urothelial carcinoma

Exclusion criteria

Exclusion criteria: nothing

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactTakeshi Azuma

Tokyo Metropolitan Tama Medical Center Urology

tazuma-tky@umin.ac.jp042-323-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026